Pleuromutilin conjugate T7

Pleuromutilin conjugate T7 (Compound T7) (0-128 μg/mL; 16-18 h) exhibits potent broad-spectrum antibacterial activity, with MIC_s of 0.125-2 μg/mL against clinical MRSA and MDR-EF isolates, 0.25-32 μg/mL against Gram-positive reference strains, and 8-64 μg/mL against most tested Gram-negative strains^[1].
Pleuromutilin conjugate T7 (2-16× MIC; 0-48 h) exhibits rapid, dose-dependent bactericidal activity against MRSA ATCC 43300, with complete bacterial eradication within 24 h at 8× MIC and within 48 h at 4× MIC^[1].
Pleuromutilin conjugate T7 (0.5-4× MIC; 48 h) exhibits dose-dependent antibiofilm activity against MRSA ATCC 43300, reducing biofilm levels by up to 63.1% at 4× MIC^[1].
Pleuromutilin conjugate T7 (2-4× MIC; 16-18 h) disrupts the cell membrane integrity of MRSA ATCC 43300 in a concentration-dependent manner, as shown by increased EthD-III staining at 2× MIC and 4× MIC^[1].
Pleuromutilin conjugate T7 (4× MIC; 24 h) induces significant morphological alterations in MRSA ATCC 43300, including reduced adhesion, disrupted cell connections, and surface fissuring^[1].
Pleuromutilin conjugate T7 (4× MIC; 24 h) impairs cell wall synthesis in MRSA ATCC 43300, resulting in reduced cell wall thickness and cracked cellular cross-sections^[1].
Pleuromutilin conjugate T7 (0.5× MIC; 14 h) exerts a multimodal antibacterial mechanism against MRSA ATCC 43300, including inhibition of ABC transporters, disruption of the PTS and cell wall synthesis, suppression of protein translation, and attenuation of virulence and adhesion factors^[1].
Pleuromutilin conjugate T7 (0.5-1× MIC; 14 h) downregulates the expression of virulence and adhesion-related genes (fnbA, fnbB, hlaα) in MRSA ATCC 43300, validating transcriptomic findings^[1].
Pleuromutilin conjugate T7 (64 μg/mL; 2 h) exhibits minimal hemolytic activity against rabbit red blood cells, comparable to the vehicle control^[1].
Pleuromutilin conjugate T7 (24 h) has a favorable cellular safety profile, with a CC₅₀ >12.32 μg/mL against human 293T and WI38 cell lines, which is substantially higher than its MIC against MRSA (0.125-2 μg/mL)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.